Treated with 0.002-50 μM Eltrombopag for 4 h, Eltrombopag effectively inhibits murine BAF3 cells with human TpoR with an EC50 value of 0.27 μM^[1].

Eltrombopag (30 μM; 120 min) affects the activities of p-STAT5 in N2C-Tpo cells and in megakaryocytes^[1].

Treated with 0.1 nM-10 μM Eltrombopag for 2 days, Eltrombopag promotes BAF3/hTpoR cells proliferation after incubated for 2 days with an EC50 of 0.03 μM^[1].

Otherwise, Eltrombopag efficiently inhibits Pneumococcal growth with MIC50 of 0.3 mg/L, but shows no activity against Gram-negative bacteria^[3].

In vitro studies reveal that Eltrombopag, at concentrations ranging from 0 to 200 mg/L over a 24-hour period in Caco-2 and HepG2 cells, suppresses the growth of Staphylococcus aureus, achieving a minimum inhibitory concentration (MIC50) of 1.5 mg/L. Its efficacy increases in combination with Vancomycin, lowering the MIC50 to 1.2 mg/L^[3].

Eltrombopag, at a dosage of either 0 or 10 μg/mL applied over 72 hours, significantly induces cell cycle arrest at the G0/G1 phase in Huh7 cells^[5].

Additionally, Eltrombopag demonstrates anti-proliferative effects against HCC cell lines when administered at concentrations ranging from 0.1 to 100 μg/mL over a 72-hour period^[5].

In vitro studies reveal that Eltrombopag, at concentrations ranging from 0 to 200 mg/L over a 24-hour period in Caco-2 and HepG2 cells, suppresses the growth of Staphylococcus aureus, achieving a minimum inhibitory concentration (MIC50) of 1.5 mg/L. Its efficacy increases in combination with Vancomycin, lowering the MIC50 to 1.2 mg/L^[3].